Idera Pharmaceuticals Inc (NASDAQ:IDRA)
Idera Pharmaceuticals Inc (NASDAQ:IDRA) begins 2017 with a clear plan. It is well-funded, sports a growing and robust pipeline, and anticipates offering strong near-term catalysts. The firm starts the year with more than $100 million in cash, which is adequate to advance its distinct pipeline well into H2 2018.
Idera’s prime drug candidate ‘IMO-2125’, targeting refractory melanoma, continues offering blockbuster-like results beginning from the pre-clinical phase to the existing Phase 1/2 clinical studies. Idera is working aggressively to extend the signs for IMO-2125 to resolve numerous cancer and solid tumors in together with popular checkpoint inhibitors like KEYTRUDA.
The firm, a leader in antisense technology, has advanced a third Generation Antisense technology base, which is anticipated to be introduced in H2 2017. Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a clinical-stage biopharma firm advancing novel nucleic acid based treatments for the cure of rare diseases and also certain cancers.
Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s proprietary technology comprises utilizing a TLR-targeting technology to get synthetic oligonucleotide-based medicine candidates to act by moderating the activity of definite TLRs. In addition to its TLR plans, the company has advanced a third Generation Antisense technology base using its technology to restrict the creation of disease-associated proteins by aiming RNA.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) entered 2016 after showcasing positive clinical data from the ongoing Phase 1/2 study of its then lead medicine candidate ‘IMO-8400’ in patients with Waldenstrom’s macroglobulinemia at the Annual Meeting of the ASH. The report first took the shares price to $4.4 per share. However, after the preliminary excitement, the stock declined until September 2016, when it again jumped to over $3 per share again.
The report that the firm’s Toll-like receptor agonist drug candidate ‘IMO-2125’ showed encouraging clinical activity in people with metastatic melanoma. It was well tolerated, and that was the reason for the jump in shares price on September 26, 2016. IMO-2125 was assessed in combination with ipilimumab on subjects who have not responded prior PD-1 therapy,
As per Idera, the patient population in those trials had minimal alternatives and low anticipation of clinical reaction with ipilimumab treatment only. The most outstanding outcome was that three of the four people with cutaneous melanoma stood as responders with one CR and 2 PR.
Vincent Milano, the CEO of Idera Pharmaceuticals Inc (NASDAQ:IDRA), reported that they have closed pre-clinical tasks in a broad scope of different tumor types to assess the theory of intra-tumoral administration of ‘IMO-2125’.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.